Physician profile
John Anaya, II
NPI 1225533557
$1,626.26
in general payments reported to CMS, 2019-2025
22 companies · $59.82 in 2025
The $59.82 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30.01 · 2020: $24.76 · 2021: $572 · 2022: $771 · 2023: $128 · 2024: $40.90 · 2025: $59.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $936.04 | 2021-2022 | |
| Glaxosmithkline, LLC. | $122.11 | 2022 | |
| Mallinckrodt Hospital Products INC. | $58.96 | 2020-2023 | Terlivaz, Acthar |
| Pfizer INC. | $57.07 | 2021 | |
| Calliditas Therapeutics US INC. | $48.42 | 2023-2024 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $44.18 | 2021-2022 | |
| Astellas Pharma US INC | $41.84 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.80 | 2021 | |
| Amgen INC. | $31.36 | 2023 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $30.39 | 2021-2022 | |
| United Therapeutics Corporation | $28.01 | 2021 | |
| Veloxis Pharmaceuticals, INC. | $22.45 | 2025 | Envarsus |
| Ani Pharmaceuticals, INC. | $20.77 | 2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $20.54 | 2023 | |
| Genzyme Corporation | $18.58 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $17.21 | 2021 | |
| Sandoz INC. | $17.17 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.60 | 2025 | Livtencity |
| Otsuka America Pharmaceutical, INC. | $15.94 | 2024 | Jynarque |
| Novo Nordisk INC | $15.58 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.81 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Anaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.